Acadia Pharmaceuticals (ACAD) Cash from Operations Growth (5y) (2015 - 2026)
Acadia Pharmaceuticals (ACAD) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Acadia Pharmaceuticals | 4.35 Bn | 3.50 Bn | 243.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.73% |
| Dec 31, 2025 | -12.13% |
| Sep 30, 2025 | 39.37% |
| Jun 30, 2025 | 30.15% |
| Mar 31, 2025 | 19.28% |
| Dec 31, 2024 | 27.42% |
| Sep 30, 2024 | 39.88% |
| Jun 30, 2024 | 21.53% |
| Mar 31, 2024 | 19.66% |
| Dec 31, 2023 | 33.15% |
| Sep 30, 2023 | -6.88% |
| Jun 30, 2023 | 17.09% |
| Mar 31, 2023 | 16.89% |
| Dec 31, 2022 | 4.41% |
| Sep 30, 2022 | 58.41% |
| Jun 30, 2022 | 25.94% |
| Mar 31, 2022 | -1.58% |
| Dec 31, 2021 | 17.69% |
| Sep 30, 2021 | 19.11% |
| Jun 30, 2021 | 14.90% |